PALI

Palisade Bio Inc. (PALI) | Rumor.io

Palisade Bio

PALI

Attention (50-day avg)0%

Attention rank (50-day avg)#1,777

Bullish sentiment (50-day avg)85%

Price to earnings ratio2.31

Market capitalization261.4M

Earnings per share0.65

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-16.8M

Social

What share of all stock conversation is about PALI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% +0

Jun 29

Palisade Bio's ($PALI) IND for PALI-2108, an ulcerative colitis treatment, has been cleared by the FDA, enabling a global Phase 2 ASCENTRA-UC clinical trial.
The ASCENTRA-UC study is expected to enroll approximately 204 patients and test 15 mg and 30 mg once-daily doses versus placebo, with enrollment anticipated in H2 2026.
The FDA clearance has led to a significant increase in $PALI's stock price, with some investors expressing optimism about the company's potential.

Generated by AI

Sentiment

Of the messages about PALI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	73.91% -8.35	84.96% -15.04	81.97% +39.72
Bearish	—	26.09% +8.35	15.04% +15.04	18.03% -39.72

Bullish· Dec 29

Palisade Bio, Inc. (PALI) received an Overweight rating and a $25 target from Piper Sandler, citing strong potential for its Crohn’s disease drug PALI-2108.
Piper's $25 target price for PALI implies a tenfold increase in the share price, with the company's market cap potentially reaching $4 billion.
PALI has shown strong technical indicators, including a bullish pennant formation, a strong MACD and RSI, and a significant volume day, making $2.77 a potential next level with a big leap to $3.50 if it breaks.

Bearish· Oct 1

The company's massive dilution of 171M new shares at $0.70 may lead to a price drop of -58%.
The stock's high trading volume of 85 million, combined with a looming reverse split, may cause the price to drop further.
The company's low float and large offering may lead to a price drop once the offering closes and holders take profits.

Generated by AI

Topics

Of the messages about PALI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	88.24%	97.73%	45.83%
Technical Analysis	0%	11.76%	2.27%	16.21%
Analysts	0%	0%	0%	21.05%
Controversies	0%	0%	0%	0.45%
Earnings	0%	0%	0%	0.03%
Macro	0%	0%	0%	16.43%

Announcements· Apr 5

Palisade Bio, Inc. ($PALI) has announced the enrollment of the first patient in its Newsoara Phase 3 clinical trial evaluating LB1148.
The Newsoara Phase 3 clinical trial is evaluating the efficacy and safety of LB1148 in treating gastrointestinal diseases.
The clinical trial is a significant milestone for Palisade Bio, Inc. as it moves forward with its development of LB1148 as a potential treatment for gastrointestinal diseases.

Technical Analysis· Jan 17

$PALI is expected to swing higher as long as it trades within the current gap, with a target of $3.65+.
A triple bottom pattern has formed on the 5-minute chart, indicating potential strength for $PALI.
$PALI is setting up for another big breakout in the coming days, with a potential price target of $3.50 or more.

Generated by AI

Community

Of the messages about PALI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	87.5%	68.2%	44.5%
Newcomers	0%	12.5%	31.8%	55.5%

Regulars· May 24

Palisade Bio's two ongoing clinical trials, LB1148, are expecting topline data readouts, which could be a major catalyst for the stock.
The company has received a decision to grant a European patent titled "STABLE NEURAL STEM CELLS COMPRISING AN EXOGENOUS POLYNUCLEOTIDE CODING FOR A GROWTH FACTOR AND METHODS OF USE THEREOF", which could have significant implications for the company's technology.
The stock has been experiencing significant price movements, with a recent 11.68% drop, and some traders are speculating about a potential "scale type" move, but caution is advised.

Newcomers· Apr 5

Palisade Bio's LB1148 has started its Phase 3 clinical trial, marking a significant step in its development process.
The company's quarterly revenue growth rate YoY is 0.00%, ranking 2823 out of 5748 companies in the database.
The enrollment of the first patient in the Newsoara Phase 3 clinical trial is a positive development for Palisade Bio and its investors.

Generated by AI

Palisade Bio (NASDAQ:PALI) said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn’s disease after completing its Phase I program. Chief Executive Officer JD Finley said PALI-2108 is a once-daily oral phosphodiesterase 4, or PDE4, inhibitor de

2d agoYahoo Finance

Palisade Bio Gets Clearance for Phase 2 Trial of Ulcerative Colitis Treatment in Canada

Palisade Bio (PALI) has obtained clearance from Health Canada for its global phase 2 study evaluatin

6d agoYahoo Finance

Palisade Bio receives Health Canada clearance for UC trial

6d agoInvesting.com

Palisade Bio Gets FDA Clearance for PALI-2108 in Crohn's Disease

Palisade Bio (PALI) said the US Food and Drug Administration cleared its investigational new drug ap

7d agoYahoo Finance

Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD

ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn’s diseaseFirst patient dosing targeted for Q1 2027; primary...

7d agomarkets.businessinsider.com

FDA clears Palisade Bio’s phase 2 trial for Crohn’s disease drug

7d agoInvesting.com

Also Discussed

Investors talking about PALI also mention

#	Name	Attention
1	Ani Pharmaceuticals, Inc.ANIP	0%new
2	BCLI - Brainstorm Cell Therapeutics Inc.	——
3	Stem, Inc.STEM	0%0
4	Biodexa Pharmaceuticals plc ADRBDRX	0%+0
5	Opus Genetics Inc.OCUP	0%0
6	CDMO - Avid Bioservices, Inc.	——
7	NAVB - Navidea Biopharmaceuticals, Inc.	——
8	Catalyst Pharmaceuticals Inc.CPRX	0%new
9	Gulf Resources, Inc.GURE	0%new
10	Primo Water CorporationPRMW	0%0

Palisade Bio Inc.

Healthcare
Biotechnology

Palisade Bio Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for inflammatory and fibrotic diseases. Its lead program, PALI-2108, is a once-daily oral phosphodiesterase-4 (PDE4) inhibitor prodrug designed for targeted activation in the ileum and colon, with an emphasis on localized treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. The company’s current pipeline also includes additional gastrointestinal-focused programs aimed at protecting the intestinal barrier and addressing postoperative complications. Palisade Bio works with research and development partners to advance its drug candidates through clinical studies and product development, positioning the company within the specialty biopharmaceutical segment of the healthcare market.

Website

Location

4600 South Syracuse Street

Denver, CO, 80237

United States

Social

What share of all stock conversation is about PALI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% +0

Jun 29

Palisade Bio's ($PALI) IND for PALI-2108, an ulcerative colitis treatment, has been cleared by the FDA, enabling a global Phase 2 ASCENTRA-UC clinical trial.
The ASCENTRA-UC study is expected to enroll approximately 204 patients and test 15 mg and 30 mg once-daily doses versus placebo, with enrollment anticipated in H2 2026.
The FDA clearance has led to a significant increase in $PALI's stock price, with some investors expressing optimism about the company's potential.

Generated by AI

Sentiment

Of the messages about PALI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	73.91% -8.35	84.96% -15.04	81.97% +39.72
Bearish	—	26.09% +8.35	15.04% +15.04	18.03% -39.72

Bullish· Dec 29

Palisade Bio, Inc. (PALI) received an Overweight rating and a $25 target from Piper Sandler, citing strong potential for its Crohn’s disease drug PALI-2108.
Piper's $25 target price for PALI implies a tenfold increase in the share price, with the company's market cap potentially reaching $4 billion.
PALI has shown strong technical indicators, including a bullish pennant formation, a strong MACD and RSI, and a significant volume day, making $2.77 a potential next level with a big leap to $3.50 if it breaks.

Bearish· Oct 1

The company's massive dilution of 171M new shares at $0.70 may lead to a price drop of -58%.
The stock's high trading volume of 85 million, combined with a looming reverse split, may cause the price to drop further.
The company's low float and large offering may lead to a price drop once the offering closes and holders take profits.

Generated by AI

Topics

Of the messages about PALI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	88.24%	97.73%	45.83%
Technical Analysis	0%	11.76%	2.27%	16.21%
Analysts	0%	0%	0%	21.05%
Controversies	0%	0%	0%	0.45%
Earnings	0%	0%	0%	0.03%
Macro	0%	0%	0%	16.43%

Announcements· Apr 5

Palisade Bio, Inc. ($PALI) has announced the enrollment of the first patient in its Newsoara Phase 3 clinical trial evaluating LB1148.
The Newsoara Phase 3 clinical trial is evaluating the efficacy and safety of LB1148 in treating gastrointestinal diseases.
The clinical trial is a significant milestone for Palisade Bio, Inc. as it moves forward with its development of LB1148 as a potential treatment for gastrointestinal diseases.

Technical Analysis· Jan 17

$PALI is expected to swing higher as long as it trades within the current gap, with a target of $3.65+.
A triple bottom pattern has formed on the 5-minute chart, indicating potential strength for $PALI.
$PALI is setting up for another big breakout in the coming days, with a potential price target of $3.50 or more.

Generated by AI

Community

Of the messages about PALI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	87.5%	68.2%	44.5%
Newcomers	0%	12.5%	31.8%	55.5%

Regulars· May 24

Palisade Bio's two ongoing clinical trials, LB1148, are expecting topline data readouts, which could be a major catalyst for the stock.
The company has received a decision to grant a European patent titled "STABLE NEURAL STEM CELLS COMPRISING AN EXOGENOUS POLYNUCLEOTIDE CODING FOR A GROWTH FACTOR AND METHODS OF USE THEREOF", which could have significant implications for the company's technology.
The stock has been experiencing significant price movements, with a recent 11.68% drop, and some traders are speculating about a potential "scale type" move, but caution is advised.

Newcomers· Apr 5

Palisade Bio's LB1148 has started its Phase 3 clinical trial, marking a significant step in its development process.
The company's quarterly revenue growth rate YoY is 0.00%, ranking 2823 out of 5748 companies in the database.
The enrollment of the first patient in the Newsoara Phase 3 clinical trial is a positive development for Palisade Bio and its investors.

Generated by AI

Palisade Bio

Social

Jun 29

Bullish· Dec 29

Bearish· Oct 1

Announcements· Apr 5

Technical Analysis· Jan 17

Regulars· May 24

Newcomers· Apr 5

Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s

Palisade Bio Gets Clearance for Phase 2 Trial of Ulcerative Colitis Treatment in Canada

Palisade Bio receives Health Canada clearance for UC trial

Palisade Bio Gets FDA Clearance for PALI-2108 in Crohn's Disease

Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD

FDA clears Palisade Bio’s phase 2 trial for Crohn’s disease drug

Also Discussed

Palisade Bio Inc.

Company Information

Location

Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s

Palisade Bio Gets Clearance for Phase 2 Trial of Ulcerative Colitis Treatment in Canada

Palisade Bio receives Health Canada clearance for UC trial

Palisade Bio Gets FDA Clearance for PALI-2108 in Crohn's Disease

Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD

FDA clears Palisade Bio’s phase 2 trial for Crohn’s disease drug

Also Discussed

Social

Jun 29

Bullish· Dec 29

Bearish· Oct 1

Announcements· Apr 5

Technical Analysis· Jan 17

Regulars· May 24

Newcomers· Apr 5